

1 **Interaction of tryptophan-related compounds with ABCG2 transporter:**
2 **comprehensive analysis of tryptophan metabolome in milk**

3 Alba Maria Garcia-Lino^{*a}, Alex Gomez-Gomez^{*b}, Dafne Garcia-Mateos^a, Alvaro de la
4 Fuente^a, Ana Isabel Alvarez^a, Oscar J. Pozo^b and Gracia Merino^a.

5 ^aDepartment of Biomedical Sciences-Physiology, Veterinary Faculty, Animal Health Institute
6 (INDEGSAL), University of Leon, Campus de Vegazana, Leon, Spain.

7 ^bIntegrative Pharmacology and Systems Neuroscience Group, IMIM, Hospital del Mar, Doctor Aiguader
8 88, Barcelona, Spain.

9 *Both authors contributed equally to this work

10

11 **Corresponding author:**

12 Dra. Gracia Merino Peláez

13 Department of Biomedical Sciences-Physiology, Veterinary Faculty, University of Leon
14 24071, Campus de Vegazana, Leon, Spain.

15 Phone: +34-987291263; Fax: +34-987291267; E-mail: gmerp@unileon.es

16

17 **Running title:** Interaction of tryptophan metabolites with ABCG2

18

19 **Funding sources:** This study was supported by the research projects AGL2015-65626-R
20 (MINECO/FEDER, UE) and RTI2018-100903-B-I00 (AEI/FEDER, UE) and by the
21 predoctoral grants from the Ministry of Economy, Industry and Competitiveness (BES-2016-
22 077235 grant to AMGL), and from Spanish Ministry of Education, Culture and Sport
23 (FPU14/05131 grant to DGM). The research contract of OJP from the Spanish Health
24 Institute Carlos III (CPII16/00027) is also acknowledged.

25

26 **Conflict of interest:** none

27

28 **Keywords:** ABCG2, tryptophan, kynurenine, milk, kynurenic acid, polymorphism.

29

30

31

32

33 **Abstract**

34 Milk is the main source of the essential amino acid tryptophan and its metabolites for
35 sucklings. The main pathway in tryptophan metabolism is the kynurenine pathway that
36 generates several bioactive metabolites with relevant health effects, including prevention of
37 neurodegenerative disorders. ABCG2 transporter participates in milk secretion of different
38 compounds. Our aim was to provide a comprehensive overview of the *in vitro* and *in vivo*
39 interactions between tryptophan-related compounds and ABCG2. Tryptophan metabolome
40 was analysed in milk and plasma from wild-type and *Abcg2*^{-/-} mice using liquid
41 chromatography-tandem mass spectrometry. Our results show that *Abcg2* mediates the
42 secretion of kynurenic acid, kynurenine, anthranilic acid and xanthurenic acid into milk.
43 Complementary metabolome analysis revealed that the bovine ABCG2 Y581S
44 polymorphism increases kynurenine concentration in cow milk. All these results show the
45 relevance of the interaction of ABCG2 and tryptophan-related compounds present in milk
46 and its potential effect on health, mainly in postnatal development.

47

48

49

50

51

52

53

54

55

56

57

58 1. Introduction

59 Milk contains a number of nutrients and bioactive ingredients that play an important role
60 in health. Some of these important nutrients and bioactive ingredients of milk are L-
61 tryptophan (Trp) and its metabolites. It is worth noting that breast milk is the only source of
62 this essential amino acid in breast-fed infants (Schneider, Mutungi, & Cubero, 2018). Trp is
63 an aromatic amino acid critical for protein synthesis; in addition to this essential role, it is
64 the precursor of several bioactive compounds with important physiological roles (Cervenka,
65 Agudelo, & Ruas, 2017). Trp metabolism proceeds mainly by kynurenine (KYN) and
66 serotonin (5HT) pathways (Fig. 1), and the main metabolites generated are related to broad
67 spectrum effects associated with neurodegenerative disorders, pain syndromes and
68 autoimmune diseases (Vécsei, Szalárdy, Fülöp, & Toldi, 2013). Probably the best-known
69 pathway is Trp conversion to 5HT and finally to melatonin. Both compounds have important
70 roles in the central nervous system (CNS). 5HT is an important neurotransmitter involved in
71 the control of adaptive responses in the CNS. Melatonin is a neurohormone and a powerful
72 free-radical scavenger, therefore it is an important antioxidant (Reiter et al., 2017). In
73 addition, it plays an essential role in regulating circadian rhythms related to physiological
74 functions such as sleep and blood pressure (Boutin, Audinot, Ferry, & Delagrangé, 2005).
75 Nevertheless, more than 95% of Trp is metabolized through the Kynurenine Pathway (KP)
76 in the liver (Badawy, 2019). This pathway generates a range of metabolites, collectively
77 known as kynurenines, involved in immune response, inflammation and neurotransmission
78 (Stone, Stoy, & Darlington, 2013). Most of them are neuroactive and show relevant roles in
79 the regulation of NMDA (N-methyl-D-aspartate) receptor function and the production of free
80 radicals (Nayak & Buttar, 2016). The presence of some of these metabolites in the diet
81 could have important effects on biological processes. For example, an excess of L-KYN in
82 diet could affect neuronal development in young (Pocivavsek, Wu, Elmer, Bruno, &
83 Schwarcz, 2012).

84 Thus, the content of Trp metabolites in milk might have important effects on human
85 health. The presence of a large number of metabolites and xenobiotics in milk is mediated
86 by two transporter superfamilies: ATP-binding cassette (ABC) and Solute Carrier (SLC)
87 transporters (García-Lino, Álvarez-Fernández, Blanco-Paniagua, Merino, & Álvarez, 2019).
88 In particular, ABCG2/BCRP mediates the active secretion of xenobiotics and several
89 vitamins into milk (van Herwaarden et al., 2007). ABCG2 is present in a multitude of tissues

90 which affect the body distribution of a wide range of molecules including chemotherapeutic
91 (mitoxantrone, methotrexate) and non-chemotherapy drugs (nitrofurantoin,
92 fluoroquinolones), as well as endogenous and dietary compounds such as flavonoids,
93 porphyrins, estrone-3-sulfate and uric acid (Safar, Kis, Erdo, Zolnerciks, & Krajcsi, 2019).
94 However, its role in the regulation of the milk content of Trp metabolites has not been
95 explored.

96 The function of ABCG2 in regulating milk content can be altered by the presence of
97 several polymorphisms. In cattle, Cohen-Zinder et al. (2005) reported an SNP encoding a
98 substitution of a Ser by Tyr at aminoacidic position 581 (Y581S) described as an *in vitro*
99 and *in vivo* gain-of-function polymorphism (Otero, 2015; Real et al., 2011), which is directly
100 involved in milk quality affecting the presence of ABCG2 substrates in cow milk (García-
101 Lino et al., 2019). In humans, several genetic analyses have demonstrated that single
102 nucleotide polymorphisms (SNPs) leading to ABCG2 deficiency are essential in the
103 pathogenesis of hyperuricemia and gout (Woodward et al., 2009). The Q141K variant yields
104 to decreased ABCG2 protein expression and influences risk of hyperuricemia and gout.
105 Because of this, the Q141k variant has been studied as a potential therapeutic target
106 (Woodward et al., 2009). Although there is some evidence linking hyperuricemia to changes
107 in Trp levels (Liu et al., 2011), and Dankers et al. (Dankers et al., 2013) have suggested
108 that kynurenic acid (KYNA) could interact with human ABCG2, the interaction between
109 ABCG2 and Trp metabolites has not been fully established.

110 The aim of this work was to study the interaction of Trp-related compounds with ABCG2
111 transporter through the analysis of Trp metabolome in plasma and milk of wild-type and
112 *Abcg2*^{-/-} mice. The outcome was corroborated by *in vitro* transport studies with cells
113 overexpressing murine *Abcg2*. A complementary Trp metabolome analysis was performed
114 in plasma and milk from cows carrying the polymorphism Y581S and non-carrier animals.

115

116

117

118

119 **2. Materials and methods**

120 *2.1. Standards and chemicals*

121 Reference standards of leucine (Leu), isoleucine (Ile), Trp, 5HT, melatonin, serotonin
122 (5HT), 5-hydroxyindolacetic acid (5HIAA), KYN, KYNA, xanthurenic acid (XA) and
123 anthranilic acid (AA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Kynurenic
124 acid-d5, phenylalanine-d5 and serotonin-d5 were supplied by Toronto Research Chemicals
125 (Toronto, Canada). Tyrosine-d4, tryptophan-d5, 5-hydroxyindolacetic acid-d4, and
126 kynurenine-13C6 were from Alsachim (Illkirch-Graffenstaden, France). All the other
127 chemicals were analytical grade and obtained from commercial sources.

128 *2.2. Animals*

129 Animals were housed and handled according to institutional guidelines complying with
130 European legislation (2010/63/EU). Experimental procedures were approved by the Animal
131 Care and Use Committee of the University of León and the Junta de Castilla y León
132 ULE_011_2016 and ULE_002_2017.

133 *Abcg2*^{-/-} and wild type female mice aged between 8 and 17 weeks, all of them >99% FVB
134 genetic background (n = 9 – 12), were kindly provided by Dr. A. H. Schinkel (The
135 Netherlands Cancer Institute, Amsterdam, the Netherlands), and were kept in a
136 temperature-controlled environment with a 12-h light / 12-h dark cycle. Pups of
137 approximately 10 days old were separated from their mothers approximately 4 h before milk
138 collection. Oxytocin (200 µL of 1 IU/mL solution) was administered subcutaneously to
139 lactating mothers to stimulate milk production 20 min before milk sampling. Milk samples
140 were collected in the morning from the mammary glands by gentle pinching after
141 anesthesia with isoflurane. Blood samples were collected by cardiac puncture under
142 anesthesia with isoflurane and centrifuged immediately at 3000 g for 15 min. At the end of
143 the experiment, the mice were killed by cervical dislocation. Plasma and milk samples were
144 stored at -20 °C until LC-MS/MS analysis.

145 Lactating Holstein-breed cows aged between 2 and 5 years and weighing 650 to 1000 kg
146 were used. Their daily milk yield was on average 40 ± 10 kg. The normal milking routine for
147 all the animals involved milk being taken three times each day. The samples were taken at
148 a private farm located at Villalquite, Leon (Spain). The Y581S genotypes were determined

149 in accordance with the procedure described by Komisarek et al (2009) (Komisarek &
150 Dorynek, 2009). Animals were divided into 2 groups of 8 Y/S 581 heterozygous and 8 Y/Y
151 581 homozygous cows. No difference was found in age, weight, or milk yield between the
152 two sets of cows. Samples were collected from the first morning milking by mechanical
153 milking. Blood samples were collected from the tail vein and plasma was separated by
154 centrifugation at 3000 x g for 15 min. Plasma and milk samples were stored at -20 °C until
155 LC-MS/MS analysis.

156 *2.3. Sample preparation for LC-MS/MS analysis*

157 An aliquot of plasma (70 µL for mice and 150 µL for cows) or milk (between 63 and 180
158 mg for mice and 150 µL for cows) was mixed with 300 µL of acetonitrile in order to
159 precipitate the proteins. After centrifugation, the supernatant was transferred to a clean tube
160 and 50 µL of the internal standard mixture (containing kynurenic acid-d5, phenylalanine-d5,
161 serotonin-d5, tyrosine-d4, tryptophan-d5, 5-hydroxyindolacetic acid-d4, and kynurenine-
162 13C6) were added. The mixture was evaporated at room temperature under nitrogen
163 stream (<10 psi). After reconstitution with 150 µL of water, 10 µL were injected into the
164 system. The standards used for calibration were subjected to the sample procedure.

165 *2.4. Quantification of Trp related compounds by LC-MS/MS*

166 A previously described LC-MS/MS method (Marcos et al., 2016) was used for the
167 determination of Trp-related compounds in milk and plasma from mice and cows. The LC-
168 MS/MS system used to perform the analysis was an Acquity UPLC system (Waters
169 Associates, Milford, MA, USA) coupled to a TQS Micro triple quadrupole mass
170 spectrometer (Waters Associates) equipped with an electrospray ionization interface.
171 Chromatographic separation was carried out on an Acquity BEH C18 column (100 mm x
172 2.1 mm i.d., 1.7 µm) (Waters Associates) at a flow rate of 300 µL/min. Water and methanol
173 both with ammonium formate (1 mM) and formic acid (0.01% v/v) were used as mobile
174 phase solvents. A gradient elution was used for the chromatographic separation of the
175 analytes. The percentage of the organic solvent linearly changed as follows: 0 min, 1%; 0.5
176 min, 1%; 7 min, 40%; 8.5 min, 90%; 9 min, 90%; 9.5 min, 1%; 12 min, 1%. Analytes were
177 determined by SRM including 2 ion transitions for each analyte.

178

179 *2.5. Cell cultures*

180 MDCKII cells and their murine Abcg2 transduced subclones were provided by Dr. A.H.
181 Schinkel, Netherlands Cancer Institute, Amsterdam. MDCKII cells stably transduced with
182 both bovine variants (S581 and Y581) of ABCG2 were previously generated by our group
183 (Real et al., 2011). Culture conditions were as previously described (Otero, 2015; Perez et
184 al., 2013).

185 *2.6. Transport studies*

186 Transepithelial transport assays using Transwell plates were carried out as described
187 elsewhere (Otero, 2015; Perez et al., 2013) with minor modifications. Cells were grown for
188 3 days after seeding on microporous polycarbonate membrane filters at a density of $1.0 \times$
189 10^6 cells per well. To check the tightness of the monolayer, transepithelial resistance was
190 measured in each well using a Millicell ERS ohmmeter (Millipore). Transport medium
191 consisted of Hanks' Balanced Salt solution (Sigma-Aldrich) supplemented with 4-(2-
192 hydroxyethyl)-1-piperazineethanesulfonic acid, HEPES (25 mM). Two hours before the start
193 of the experiment, medium at both the apical (AP) and basolateral (BL) sides of the
194 monolayer was replaced with 2 mL of transport medium without serum, HANKs solution
195 supplemented, either with or without the specific ABCG2 inhibitor Ko143 (1 μ M). The
196 experiment started when medium in either the AP or BL compartment was replaced with
197 fresh medium containing the different compounds at a concentration of 10 μ M. Cells were
198 incubated at 37 °C in 5% CO₂ and 100 μ L aliquots of culture media were taken at t=1, 2, 3
199 and 4 h, ours and this volume was replaced with fresh medium. The samples were stored at
200 -20 °C. Concentrations of studied compounds were subsequently determined by HPLC.
201 Active transport across MDCKII monolayers was expressed by the relative transport ratio
202 (R), defined as apically directed transport percentage divided by basolaterally directed
203 translocation percentage, after 4 h.

204 *2.7. High Performance Liquid Chromatography (HPLC) Analysis*

205 Analysis of samples to determine the concentrations of the studied compounds in the
206 transepithelial transport assays were carried out by HPLC analysis. The chromatographic
207 system consisted of a Waters 2695 separation module and a Waters 2998 UV photodiode
208 array detector. Fifty μ L of the culture medium was injected directly into the HPLC system.

209 Separation of the samples was performed on a reverse-phase column (Atlantis® T3 3 µm,
210 4.6x150 mm). The mobile phase consisted of 0.14 % trifluoroacetic acid:acetonitrile (80:20),
211 the flow rate of the mobile phase was set to 0.8 mL/min, and UV absorbance was
212 measured at 238 nm. The temperature of the samples was 4 °C. Standard samples were
213 prepared in the appropriate drug-free matrix, yielding a concentration range from 0.039
214 µg/mL to 10 µg/mL, with coefficients of correlation >0.99. The limit of quantification was in
215 the range of 0.02 – 0.03 µg/mL and the limit of detection was in the range of 0.005 – 0.014
216 µg/mL for all the compounds. Both were calculated by the method described by Taverniers
217 et al. (Taverniers, I., De Loose, M., Van Bockstaele, 2004).

218 *2.8. Statistical analysis*

219 Comparisons between groups were performed by the Student's t-test (normal variables)
220 and the Mann-Whitney U test (not normally distributed variables). All analyses were carried
221 out on the assumed significance level of $p \leq 0.05$ using SPSS Statistics software (v. 24.0;
222 IBM, Armonk, New York, NY, USA). The results are shown as mean \pm standard deviation
223 (SD).

224

225

226

227

228

229

230

231

232

233

234

235

236

237 **3. Results**

238 *3.1. Determination of Trp-related compounds in milk from Abcg2^{-/-} and wild-type mice*

239 To examine the role of ABCG2 in the transport of Trp metabolites into milk, we collected
240 milk and plasma samples of wild-type and Abcg2^{-/-} female mice.

241 The targeted LC-MS/MS method included 10 analytes. These Trp-related analytes were
242 divided into three different classes based on their biological origin (Fig. 1): (a) large neutral
243 amino acids (LNAA) competitors of Trp; (b) metabolites belonging to the serotonin pathway;
244 (c) metabolites from the kynurenine pathway.

245 All the compounds were detected in all plasma and milk samples, with the exception of
246 Trp in milk and melatonin in plasma and milk (Table 1). There were no differences in
247 plasma between wild-type and Abcg2^{-/-} mice for any compound. Nevertheless, a higher
248 secretion into milk concentration of KYN, KYNA, XA, AA and 5HIAA was observed in wild-
249 type compared to Abcg2^{-/-} mice (Table 1). These differences were especially high for XA
250 and KYNA, with a concentration in milk of almost 10-fold higher (75 ± 40 ng/mg versus $7.8 \pm$
251 4.7 ng/mg) and 5-fold higher (42 ± 8 ng/mg versus 9.1 ± 3.0 ng/mg) in wild-type and Abcg2^{-/-}
252 mice, respectively. Higher milk-to-plasma ratios were also obtained for these five
253 metabolites in wild-type compared to Abcg2^{-/-} mice, except for 5HIAA. These data indicate
254 that Abcg2 plays a substantial role in the secretion of KYN, KYNA, XA and AA into milk.

255 *3.2. Effect of the bovine ABCG2 polymorphism Y581S SNP on secretion into milk of Trp-*
256 *related compounds*

257 A similar analysis was performed on cows carrying the Y581S polymorphism and on
258 non-carrier animals (Table 2). All the analytes were detected in all plasma and milk samples
259 with the exception of AA, which was not detected in any sample, and 5HT, which was not
260 detected in any milk sample. There were no differences in plasma levels between Y/Y 581
261 and Y/S 581 cows for any compound tested. Significant differences were found only in milk
262 for KYN concentrations (Table 2, Fig. 2). KYN milk concentrations were 2-fold higher in Y/S
263 (4.6 ± 1.8 ng/mL) compared with Y/Y cows (2.4 ± 1.0 ng/mL). The milk-to-plasma ratio for
264 KYN in Y/S cows was 2-fold higher than in Y/Y cows (0.004 ± 0.002 versus 0.002 ± 0.001).
265 This indicates that the polymorphism Y581S affects the *in vivo* active transport of KYN into
266 cow milk.

267

268 3.3. *Transport of Trp metabolites in MDCKII cell models transduced with murine Abcg2*

269 To corroborate the metabolomic study in mice, a transport assay using parental MDCKII
270 and its subclones transduced with murine Abcg2 was performed to study the role of this
271 protein in the process. KYN, KYNA, XA and AA were tested *in vitro* due to *in vivo* evidence
272 of Abcg2 involved in their milk secretion (Table 2). Trp itself was also included.

273 In the MDCKII parental cell line, most of the molecules showed similar apically and
274 basolaterally directed translocation (Fig. 3A). However, parental MDCKII cells displayed a
275 high basolaterally directed translocation of KYN and Trp, whereas apically directed
276 translocation was very low, indicating the potential presence of an absorptive KYN and Trp
277 transport process.

278 In the murine Abcg2-transduced cells (Fig. 3B), we observed for KYN, KYNA and XA
279 increased translocation from the basolateral to the apical compartment, and reduced
280 translocation from the apical to the basolateral compartment compared to parental cells,
281 with high relative transport ratios (AP/BL). For AA, a low transport ratio similar to the
282 parental cells was obtained. The apical transport of KYN, KYNA and XA by Abcg2 was
283 completely inhibited by Ko143, a selective Abcg2 inhibitor (data not shown).

284 From this, we can confirm that KYN, KYNA and XA are good *in vitro* substrates of murine
285 Abcg2.

286 3.4. *Transport of KYN in MDCKII cell models transduced both bovine variants (Y581 and*
287 *S581)*

288 To corroborate the role of the bovine Y581S polymorphism in the transport of KYN,
289 transport assays were performed using polarized MDCKII parental cells and their subclones
290 transduced with both bovine ABCG2 variants (S581 and Y581) (Fig. 4). The relative
291 transport ratio of KYN was significantly higher in the S581 expressing cells versus parental
292 cells (1.08 ± 0.25 vs. 0.59 ± 0.19) since apical transport increased and basolateral transport
293 decreased compared with parental cells. However, in the case of cells expressing Y581
294 cells, no changes were observed in the transport ratio compared with parental cells,
295 indicating that KYN is not transported by this variant. Statistically significant differences
296 were found between transport ratios of both variants of bovine ABCG2, Y581 and S581
297 (0.42 ± 0.25 vs. 1.08 ± 0.25). Therefore, the differences found between two bovine variants

298 showed that the Y581S polymorphism affects the *in vitro* transport of KYN, corroborating
299 the differences found *in vivo* between carrier and non-carrier animals.

300

301 **4. Discussion**

302 In this study a targeted metabolomic analysis was performed to elucidate the role of
303 ABCG2 transport in the active secretion of Trp-related compounds in plasma and milk. The
304 relevance of the bovine Y581S polymorphism on the transport of these compounds present
305 in cow milk was also studied.

306 Due to the complication in controlling all the animal factors, such as age, nutrition and
307 time of lactation, among others, a study of the association between *in vitro* and *in vivo*
308 results is difficult, especially in cows (Otero, 2015). However, this LC-MS/MS metabolomic
309 study permits a comprehensive estimation of the effect of ABCG2 in Trp-related pathways
310 in plasma and milk in mice and cows. What is of relevance, and an advantage over other
311 studies analysing a limited number of metabolites (Cubero et al., 2005; Laeger, Görs,
312 Metges, & Kuhla, 2012), is the fact that a large number of compounds were determined.

313 The amount of L-Trp in humans is essential for maintaining health, and one of the most
314 common sources of Trp in the human diet is milk (Richard et al., 2009). Furthermore, the
315 biological activities of its derivative compounds, mainly as neuroactive molecules, adds to
316 the importance of this complete study. Focussing, therefore, on the relevance of these
317 neuroactive compounds in the diet, we performed the metabolome analysis to elucidate the
318 role of ABCG2 transport in active secretion into milk of *Abcg2*^{-/-} and wild-type lactating
319 mice. Differences in the concentrations of KYN, KYNA, XA and AA were observed in the
320 milk-to-plasma ratio between wild-type and *Abcg2*^{-/-} mice, which suggests the involvement
321 of *Abcg2* in the milk secretion of these compounds (Table 1). These results were
322 corroborated by transport assays showing that KYN, KYNA and XA are *in vitro* substrates
323 of *Abcg2* (Fig. 3). Only KYNA had been previously described as a potential *Abcg2* substrate
324 in humans (Dankers et al., 2013). Conversely, AA was not confirmed as an *in vitro*
325 substrate of ABCG2, and due to the positive results observed in the *in vivo* study, we
326 cannot exclude its *in vitro* interaction with the *Abcg2* transporter in other experimental
327 conditions.

328 Binding of substrate to ABCG2 has been shown to be dependent of hydrophobic
329 interactions, mainly between hydrogen bond acceptors (HBAs) present in substrates and
330 hydrogen bond donors (HBDs) present in the transmembrane region of the transporter,
331 among other physicochemical features (Matsson et al., 2007). In addition, Xu *et al.* (Xu et al.,
332 2015) demonstrated that binding of substrates with the ABCG2 transporter increases with
333 the number of HBAs present in the potential substrates. In our case, KYN, KYNA and XA,
334 identified as Abcg2 substrates, gave a higher number of HBAs than Trp, 5HIAA and 5HT
335 and AA (non Abcg2 substrates) (Supplementary material, Table S1).

336 Furthermore, we examined the importance of the bovine Y581S polymorphism in the
337 transport of Trp-related compounds present in cow milk, as previously reported for milk
338 secretion of fluoroquinolone drugs, antiinflammatory drugs and endogenous and dietary
339 compounds (García-Lino et al., 2019; Otero, 2015). In fact uric acid, which is related to Trp
340 levels (Dankers et al., 2013), has been previously reported as an endogenous compound
341 actively secreted into milk with a 2-fold increase in the milk plasma ratio for carrier animals
342 (Otero et al., 2016). Our data show that the transfer of KYN into milk is influenced by the
343 bovine Y581S polymorphism with an almost 2-fold increase in the concentration and milk-
344 to-plasma ratio of KYN in the Y/S animals (Fig. 2). This is the first time that differences
345 between both variants of cows, carriers and non-carriers of the Y581S polymorphism has
346 been observed for Trp-related compounds with neuroactive activity. Furthermore, these
347 results are in agreement with *in vitro* transport studies showing that cells overexpressing
348 the S581 variant transported KYN in the basolateral to apical direction more efficiently than
349 the cells with the Y581 variant (Fig. 4), indicating a higher transport capacity *in vitro* for this
350 variant.

351 Our results could have great relevance in the field of nutrition since all of these
352 metabolites show important effects on health and some of them are present in consumed
353 dairy milk. Furthermore, our results could be relevant in the early stages of development
354 where milk is the main food consumed. ABCG2 inhibitors such as drugs (Barrera et al.,
355 2013) and dietary compounds (Miguel et al., 2014) can alter the transfer of these compounds
356 into milk. In fact, these kinds of interactions mediated by ABCG2 have been observed for
357 other ABCG2 substrates. For instance, soy-enriched diet and flaxseed-enriched diet modify
358 *in vivo* milk secretion mediated by ABCG2 of the antimicrobial danofloxacin in sheep (Otero
359 et al., 2018; Perez et al., 2013). Therefore, potentially different concentrations of Trp-related

360 compounds in consumed milk due to polymorphisms or inhibition of this transporter may
361 affect the intake of these compounds by the offspring or the dairy consumer.

362 Trp-related compounds generated by KP have an important role in health due to their
363 effects on the CNS since they have been linked to several psychiatric and mental health
364 disorders such as depression and schizophrenia (Chen & Guillemin, 2009). This pathway is
365 also currently involved in immunological processes (Badawy, 2019). KYNA has proved to
366 be a neuroprotective molecule and its neuroprotective role in various experimental models
367 of neurotoxicity has been reported (Majláth, Török, Toldi, & Vécsei, 2016). There is
368 evidence in preclinical models that changes in KYNA concentrations in the brain could
369 influence the development of Huntington's disease (Okamoto et al., 2009) and
370 schizophrenia (Beggiato, Notarangelo, Sathyasaikumar, Giorgini, & Schwarcz, 2018).
371 These compounds may also have effects in other organs. Reports suggest that KYNA could
372 have a protective role in the intestinal mucosa in the framework of obstructive jaundice and
373 may protect from induced ulcers (Glavin, Bose, & Pinsky, 1989). Since we demonstrated
374 that KYNA is an ABCG2 substrate, different milk intake of KYNA due to differences in
375 ABCG2 function may affect the protective role of KYNA in several pathological conditions.

376 KYN is the main precursor of KYNA. Due to the lower permeability of KYNA in the blood-
377 brain-barrier than presented by KYN, KYN is used as a protective compound in models of
378 Huntington's disease induced by malonate and quinolinic acid (Santamaría et al., 1996).
379 However, despite the benefits in the neurodegenerative diseases provided by KYN
380 administration, several studies report that an exposure to KYN during a vulnerable period of
381 brain development causes cognitive deficits in adulthood related to schizophrenia and other
382 psychiatric diseases (Pocivavsek et al., 2012). In addition, it has been shown that a
383 continuous KYN administration during the prenatal period causes learning and memory
384 deficits in adults rats (Pocivavsek, Thomas, Elmer, Bruno, & Schwarcz, 2014). Since our
385 results show the role of ABCG2 in the presence of KYN in milk, this interaction may play an
386 important role in cognitive development of the offspring.

387 Our data may have relevant effects in other health fields. Some studies have
388 demonstrated that KYN and KYNA are endogenous ligands of the aryl hydrogen receptor
389 (AhR) (Julliard, Fechner, & Mezrich, 2014). The coupling between AhR and these
390 compounds increases concentration of TGF- β and IL-6 in early sepsis (Wirthgen & Hoeflich,

391 2015). Also, recent studies suggest that Trp-containing diet might regulate epithelial
392 homeostasis through AhR in ulcerative colitis (Islam et al., 2017).

393 In conclusion, this work demonstrates that several Trp metabolites are secreted into milk
394 by the Abcg2 transporter. It shows, in addition, that lactating dairy cows carrying the Y581S
395 polymorphism produced milk with higher amounts of KYN compared with non-carriers.

396

397 **Acknowledgments**

398 We thank Dr. A.H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The
399 Netherlands) who provided parental MDCKII cells, its murine Abcg2-transduced subclones
400 and Abcg2 knockout mice. We are grateful to Prof. James McCue for assistance in
401 language editing.

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417 **References**

- 418 Badawy, A. A. B. (2019). Tryptophan Metabolism: A Versatile Area Providing Multiple
419 Targets for Pharmacological Intervention. *Egyptian Journal of Basic and Clinical*
420 *Pharmacology*, 9. <https://doi.org/10.32527/2019/101415>
- 421 Barrera, B., González-Lobato, L., Otero, J. A., Real, R., Prieto, J. G., Álvarez, A. I., &
422 Merino, G. (2013). Effects of triclabendazole on secretion of danofloxacin and
423 moxidectin into the milk of sheep: role of triclabendazole metabolites as inhibitors of
424 the ruminant ABCG2 transporter. *Veterinary Journal*, 198(2), 429–436.
425 <https://doi.org/10.1016/j.tvjl.2013.07.033>
- 426 Beggiato, S., Notarangelo, F., Sathyaikumar, K., Giorgini, F., & Schwarcz, R. (2018).
427 Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for
428 the pathophysiology of schizophrenia. *Journal of Psychopharmacology*, 32(11), 1223–
429 1232. <https://doi.org/10.1177/0269881118805492>
- 430 Boutin, J. A., Audinot, V., Ferry, G., & Delagrangé, P. (2005). Molecular tools to study
431 melatonin pathways and actions. *Trends in Pharmacological Sciences*, 26(8), 412–419.
432 <https://doi.org/10.1016/j.tips.2005.06.006>
- 433 Cervenka, I., Agudelo, L. Z., & Ruas, J. L. (2017). Kynurenines: Tryptophan's metabolites in
434 exercise, inflammation, and mental health. *Science*, 357(6349), eaaf9794.
435 <https://doi.org/10.1126/science.aaf9794>
- 436 Chen, Y., & Guillemin, G. J. (2009). Kynurenine pathway metabolites in humans: disease
437 and healthy states. *International Journal of Tryptophan Research : IJTR*, 2, 1–19.
438 Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/22084578>
- 439 Cubero, J., Valero, V., Sánchez, J., Rivero, M., Parvez, H., Rodríguez, A. B., & Barriga, C.
440 (2005). The circadian rhythm of tryptophan in breast milk affects the rhythms of 6-
441 sulfatoxymelatonin and sleep in newborn. *Neuro Endocrinology Letters*, 26(6), 657–
442 661. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/16380706>
- 443 Dankers, A. C. A., Mutsaers, H. A. M., Dijkman, H. B. P. M., van den Heuvel, L. P.,
444 Hoenderop, J. G., Sweep, F. C. G. J., ... Masereeuw, R. (2013). Hyperuricemia
445 influences tryptophan metabolism via inhibition of multidrug resistance protein 4
446 (MRP4) and breast cancer resistance protein (BCRP). *Biochimica et Biophysica Acta -*

- 447 *Molecular Basis of Disease*, 1832, 1715–1722.
448 <https://doi.org/10.1016/j.bbadis.2013.05.002>
- 449 García-Lino, A. M., Álvarez-Fernández, I., Blanco-Paniagua, E., Merino, G., & Álvarez, A. I.
450 (2019). Transporters in the Mammary Gland—Contribution to Presence of Nutrients
451 and Drugs into Milk. *Nutrients*, 11(10), E2372. <https://doi.org/10.3390/nu11102372>
- 452 Glavin, G. B., Bose, R., & Pinsky, C. (1989). Kynurenic acid protects against
453 gastroduodenal ulceration in mice injected with extracts from poisonous Atlantic
454 shellfish. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 13(3–4),
455 569–572.
- 456 Islam, J., Sato, S., Watanabe, K., Watanabe, T., Ardiansyah, Hirahara, K., ... Shirakawa, H.
457 (2017). Dietary tryptophan alleviates dextran sodium sulfate-induced colitis through aryl
458 hydrocarbon receptor in mice. *The Journal of Nutritional Biochemistry*, 42, 43–50.
459 <https://doi.org/10.1016/j.jnutbio.2016.12.019>
- 460 Julliard, W., Fechner, J. H., & Mezrich, J. D. (2014). The aryl hydrocarbon receptor meets
461 immunology: friend or foe? A little of both. *Frontiers in Immunology*, 5, 458.
462 <https://doi.org/10.3389/fimmu.2014.00458>
- 463 Komisarek, J., & Dorynek, Z. (2009). Effect of ABCG2, PPARGC1A, OLR1 and SCD1 gene
464 polymorphism on estimated breeding values for functional and production traits in
465 Polish Holstein-Friesian bulls. *Journal of Applied Genetics*, 50(2), 125–132.
466 <https://doi.org/10.1007/BF03195663>
- 467 Laeger, T., Görs, S., Metges, C. C., & Kuhla, B. (2012). Effect of feed restriction on
468 metabolites in cerebrospinal fluid and plasma of dairy cows. *Journal of Dairy Science*,
469 95(3), 1198–1208. <https://doi.org/10.3168/jds.2011-4506>
- 470 Liu, Y., Sun, X., Di, D., Quan, J., Zhang, J., & Yang, X. (2011). A metabolic profiling
471 analysis of symptomatic gout in human serum and urine using high performance liquid
472 chromatography-diode array detector technique. *Clinica Chimica Acta; International
473 Journal of Clinical Chemistry*, 412(23–24), 2132–2140.
474 <https://doi.org/10.1016/j.cca.2011.07.031>
- 475 Majláth, Z., Török, N., Toldi, J., & Vécsei, L. (2016). Memantine and Kynurenic Acid:
476 Current Neuropharmacological Aspects. *Current Neuropharmacology*, 14(2), 200–209.

477 <https://doi.org/10.2174/1570159X14666151113123221>

478 Marcos, J., Renau, N., Valverde, O., Aznar-Laín, G., Gracia-Rubio, I., Gonzalez-Sepulveda,
479 M., ... Pozo, O. J. (2016). Targeting tryptophan and tyrosine metabolism by liquid
480 chromatography tandem mass spectrometry. *Journal of Chromatography A*.
481 <https://doi.org/10.1016/j.chroma.2016.01.023>

482 Matsson, P., Englund, G., Ahlin, G., Bergström, C. A. S., Norinder, U., & Artursson, P.
483 (2007). A global drug inhibition pattern for the human ATP-binding cassette transporter
484 breast cancer resistance protein (ABCG2). *The Journal of Pharmacology and*
485 *Experimental Therapeutics*, 323(1), 19–30. <https://doi.org/10.1124/jpet.107.124768>

486 Miguel, V., Otero, J. A., García-Villalba, R., Tomás-Barberán, F., Espín, J. C., Merino, G.,
487 ... Álvarez, A. I. (2014). Role of ABCG2 in transport of the mammalian lignan
488 enterolactone and its secretion into milk in *abcg2* knockout mice. *Drug Metabolism and*
489 *Disposition*, 42(5), 943–946. <https://doi.org/10.1124/dmd.113.055970>

490 Nayak, B. N., & Buttar, H. S. (2016). Evaluation of the antioxidant properties of tryptophan
491 and its metabolites in in vitro assay. *Journal of Complementary & Integrative Medicine*,
492 13(2), 129–136. <https://doi.org/10.1515/jcim-2015-0051>

493 Okamoto, S., Pouladi, M. A., Talantova, M., Yao, D., Xia, P., Ehrnhoefer, D. E., ... Lipton,
494 S. A. (2009). Balance between synaptic versus extrasynaptic NMDA receptor activity
495 influences inclusions and neurotoxicity of mutant huntingtin. *Nature Medicine*, 15(12),
496 1407–1413. <https://doi.org/10.1038/nm.2056>

497 Otero, J. A. (2015). Role of the ABCG2/BCRP transporter and its polymorphisms in the
498 active secretion of molecules into milk and modulation of its activity with natural
499 compounds in ruminants. *Doctoral Thesis*. Universidad de León.
500 <https://doi.org/10.18002/10612/11135>

501 Otero, J. A., García-Mateos, D., Alvarez-Fernández, I., García-Villalba, R., Espín, J. C.,
502 Álvarez, A. I., & Merino, G. (2018). Flaxseed-enriched diets change milk concentration
503 of the antimicrobial danofloxacin in sheep. *BMC Veterinary Research*, 14(1), 14.
504 <https://doi.org/10.1186/s12917-018-1341-3>

505 Otero, J. A., Miguel, V., González-Lobato, L., García-Villalba, R., Espín, J. C., Prieto, J. G.,
506 ... Álvarez, A. I. (2016). Effect of bovine ABCG2 polymorphism Y581S SNP on

507 secretion into milk of enterolactone, riboflavin and uric acid. *Animal*, 10(02), 238–247.
508 <https://doi.org/10.1017/S1751731115002141>

509 Perez, M., Otero, J. A., Barrera, B., Prieto, J. G., Merino, G., & Alvarez, A. I. (2013).
510 Inhibition of ABCG2/BCRP transporter by soy isoflavones genistein and daidzein:
511 Effect on plasma and milk levels of danofloxacin in sheep. *The Veterinary Journal*,
512 196(2), 203–208.

513 Pocivavsek, A., Thomas, M. A. R., Elmer, G. I., Bruno, J. P., & Schwarcz, R. (2014).
514 Continuous kynurenine administration during the prenatal period, but not during
515 adolescence, causes learning and memory deficits in adult rats. *Psychopharmacology*,
516 231, 2799–2809. <https://doi.org/10.1007/s00213-014-3452-2>

517 Pocivavsek, A., Wu, H. Q., Elmer, G. I., Bruno, J. P., & Schwarcz, R. (2012). Pre- and
518 postnatal exposure to kynurenine causes cognitive deficits in adulthood. *European*
519 *Journal of Neuroscience*, 35, 1605–1612. [https://doi.org/10.1111/j.1460-](https://doi.org/10.1111/j.1460-9568.2012.08064.x)
520 [9568.2012.08064.x](https://doi.org/10.1111/j.1460-9568.2012.08064.x)

521 Real, R., González-Lobato, L., Baro, M. F., Valbuena, S., de la Fuente, A., Prieto, J. G., ...
522 Merino, G. (2011). Analysis of the effect of the bovine adenosine triphosphate-binding
523 cassette transporter G2 single nucleotide polymorphism Y581S on transcellular
524 transport of veterinary drugs using new cell culture models. *Journal of Animal Science*,
525 89(12), 4325–4338. <https://doi.org/10.2527/jas.2011-3841>

526 Reiter, R. J., Rosales-Corral, S., Tan, D. X., Jou, M. J., Galano, A., & Xu, B. (2017).
527 Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas.
528 *Cellular and Molecular Life Sciences*, 74(21), 3863–3881.
529 <https://doi.org/10.1007/s00018-017-2609-7>

530 Richard, D. M., Dawes, M. A., Mathias, C. W., Acheson, A., Hill-Kapturczak, N., &
531 Dougherty, D. M. (2009). L-Tryptophan: Basic Metabolic Functions, Behavioral
532 Research and Therapeutic Indications. *International Journal of Tryptophan Research :*
533 *IJTR*, 2, 45–60.

534 Safar, Z., Kis, E., Erdo, F., Zolnerciks, J. K., & Krajcsi, P. (2019). ABCG2/BCRP: variants,
535 transporter interaction profile of substrates and inhibitors, 15(4), 313–328.
536 <https://doi.org/10.1080/17425255.2019.1591373>

- 537 Santamaría, A., Ríos, C., Solís-Hernández, F., Ordaz-Moreno, J., González-Reynoso, L.,
538 Altgracia, M., & Kravzov, J. (1996). Systemic dl-Kynurenine and probenecid
539 pretreatment attenuates quinolinic acid-induced neurotoxicity in rats.
540 *Neuropharmacology*, 35(1), 23–28. [https://doi.org/10.1016/0028-3908\(95\)00145-X](https://doi.org/10.1016/0028-3908(95)00145-X)
- 541 Schneider, N., Mutungi, G., & Cubero, J. (2018). Diet and nutrients in the modulation of
542 infant sleep: A review of the literature. *Nutritional Neuroscience*, 21(3), 151–161.
543 <https://doi.org/10.1080/1028415X.2016.1258446>
- 544 Stone, T. W., Stoy, N., & Darlington, L. G. (2013). An expanding range of targets for
545 kynurenine metabolites of tryptophan. *Trends in Pharmacological Sciences*, 34(2),
546 136–143. <https://doi.org/10.1016/j.tips.2012.09.006>
- 547 Taverniers, I., De Loose, M., Van Bockstaele, E. (2004). Trends in quality in the analytical
548 laboratory. II. Analytical method validation and quality assurance. *TrAC Trends in*
549 *Analytical Chemistry*, 23(8), 535–552. <https://doi.org/10.1016/J.TRAC.2004.04.001>
- 550 van Herwaarden, A. E., Wagenaar, E., Merino, G., Jonker, J. W., Rosing, H., Beijnen, J. H.,
551 & Schinkel, A. H. (2007). Multidrug Transporter ABCG2/Breast Cancer Resistance
552 Protein Secretes Riboflavin (Vitamin B2) into Milk. *Molecular and Cellular Biology*,
553 27(4), 1247–1253. <https://doi.org/10.1128/MCB.01621-06>
- 554 Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013). Kynurenines in the CNS: Recent
555 advances and new questions. *Nature Reviews Drug Discovery*, 12, 64–82.
556 <https://doi.org/10.1038/nrd3793>
- 557 Wirthgen, E., & Hoeflich, A. (2015). Endotoxin-Induced Tryptophan Degradation along the
558 Kynurenine Pathway: The Role of Indolamine 2,3-Dioxygenase and Aryl Hydrocarbon
559 Receptor-Mediated Immunosuppressive Effects in Endotoxin Tolerance and Cancer
560 and Its Implications for Immunoparalysis. *Journal of Amino Acids*, 2015, 973548.
561 <https://doi.org/10.1155/2015/973548>
- 562 Woodward, O. M., Köttgen, A., Coresh, J., Boerwinkle, E., Guggino, W. B., & Köttgen, M.
563 (2009). Identification of a urate transporter, ABCG2, with a common functional
564 polymorphism causing gout. *Proceedings of the National Academy of Sciences of the*
565 *United States of America*, 106(25), 10338–10342.
566 <https://doi.org/10.1073/pnas.0901249106>

567 Xu, Y., Egido, E., Li-Blatter, X., Müller, R., Merino, G., Bernèche, S., & Seelig, A. (2015).
568 Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and
569 P-Glycoprotein (ABCB1). *Biochemistry*, 54(40), 6195–6206.
570 <https://doi.org/10.1021/acs.biochem.5b00649>

571

572

573 **Figure captions**

574

575 Fig. 1. Tryptophan-related metabolites included in the target LC-MS/MS method. (a) Large
576 neutral amino acids (LNAA) competitors of Trp; (b) Kynurenine pathway and (c) Serotonin
577 pathway. Isoleucine (Ile), leucine (Leu), tryptophan (Trp), kynurenine (KYN), kynurenic acid
578 (KYNA), xanthurenic acid (XA) and anthranilic acid (AA), 5-hydroxyindolacetic acid (5HIAA),
579 serotonin (5HT).

580

581 Fig. 2. Plasma concentration (A), milk concentration (B) and milk/plasma ratio (C) of KYN in
582 Y/Y 581 and Y/S 581 cows. Samples were collected at the first routine morning milking.
583 Results are mean; error bars indicated S.D (n=8; * p<0.05).

584

585 Fig. 3. Transepithelial transport of tested compounds (10 μ M) in (A) parental MDCKII cells
586 and (B) their murine Abcg2 transduced derivative. (\circ) translocation from the apical to the
587 basolateral compartment; (\bullet) translocation from the basolateral to the apical compartment.
588 The experiment was started with the addition of each compound to one compartment
589 (basolateral or apical). Aliquots of 100 μ L were taken from the opposite compartment at t=1,
590 2, 3 and 4 h, and measured by HPLC. The fraction of each compound transported to the
591 acceptor compartment was presented as a percentage of the total amount of compound
592 added to the donor compartment at the beginning of the experiment. Results are means,
593 error bars indicated SD (n=3-8). Ratio represents the relative transport ratio (i.e. the apical
594 directed translocation divided by the basolateral directed translocation) at t=4h.

595

596 Fig. 4. Transepithelial transport of KYN (10 μ M) in polarized MDCKII parental (non-
597 transduced), MDCKII-S581-ABCG2, and MDCKII-Y581-ABCG2 monolayers. The
598 experimental was started (t=0) by replacing the medium in either the apical or basolateral
599 compartment with fresh Hanks supplemented medium containing 10 μ M KYN. Aliquots of
600 100 μ L were taken from the opposite compartment at t=1, 2, 3 and 4 h, and measured by
601 HPLC. The fraction of KYN transported to the acceptor compartment was presented as a
602 percentage of the total amount of KYN added to the donor compartment at the beginning of
603 the experiment. Results are means, error bars indicated SD (n=5). Ratio represents the
604 relative transport ratio (i.e. the apical directed translocation divided by the basolateral
605 directed translocation) at t=4h. (\circ) translocation from the apical to the basolateral
606 compartment; (\bullet) translocation from the basolateral to the apical compartment.

607

608

609

610

611 Table 1. Levels of Trp-related compounds (ng/mL) in plasma and milk samples from wild-
 612 type and *Abcg2*^{-/-} female mice (n=9-12). Milk to plasma ratio is also represented.

		Wild-type	<i>Abcg2</i> ^{-/-}	p-value
<i>Plasma</i>	Leu	24400 ± 7229	20937 ± 7925	0.292
	Ile	25209 ± 7670	21507 ± 8275	0.285
	Trp	88660 ± 11302	89831 ± 11302	0.911
	KYN	1628 ± 363	1451 ± 344	0.259
	KYNA	7.1 ± 2.5	6.6 ± 2.2	0.647
	XA	73 ± 37	69 ± 30	0.792
	AA	155 ± 98	124 ± 66	0.404
	5HT	11937 ± 5080	8643 ± 1959	0.079
	5HIAA	702 ± 138	581 ± 143	0.060
	<i>Milk</i>	Leu	497 ± 238	386 ± 282
Ile		1645 ± 515	2051 ± 684	0.250
Trp		< LOD	<LOD	-
KYN		32 ± 17	15 ± 7	0.039*
KYNA		42 ± 8	9.1 ± 3.0	< 0.001*
XA		75 ± 40	7.8 ± 4.7	0.001*
AA		36 ± 10	17 ± 7	0.01*
5HT		41 ± 22	40 ± 19	0.585
5HIAA		118 ± 24	84 ± 14	0.001*
<i>Milk to plasma</i>		Leu	0.02 ± 0.01	0.08 ± 0.18
	Ile	0.08 ± 0.02	0.53 ± 1.35	0.265
	Trp	< LOD	< LOD	-
	KYN	0.02 ± 0.01	0.01 ± 0.00	0.012*
	KYNA	6.9 ± 2.6	1.47 ± 0.51	< 0.001*
	XA	0.97 ± 0.48	0.22 ± 0.33	0.001*
	AA	0.23 ± 0.10	0.12 ± 0.04	0.008*
	5HT	0.004 ± 0.00	0.004 ± 0.00	0.794
	5HIAA	0.17 ± 0.04	0.15 ± 0.05	0.322

613 Results are expressed as means of concentration (ng/mL) ± S.D. * p<0.05 versus wild-type

614

615 Table 2. Levels of Trp-related compounds (ng/mL) in plasma and milk samples from non-
 616 carrier (Y/Y) and carrier (Y/S 581) cows (n=4). Milk to plasma ratio is also represented.

		Y/Y	Y/S	p-value
<i>Plasma</i>	Leu	38067 ± 9127	39692 ± 10952	0.751
	Ile	13559 ± 3439	13315 ± 3283	0.886
	Trp	11283 ± 3053	12348 ± 2443	0.453
	KYN	1054 ± 381	1067 ± 256	0.935
	KYNA	8.1 ± 3.4	7.1 ± 0.5	0.407
	XA	95 ± 26	108 ± 18	0.263
	5-HT	0.09 ± 0.07	0.14 ± 0.08	0.197
	5HIAA	0.011 ± 0.003	0.011 ± 0.003	0.724
	Melatonin	0.006 ± 0.004	0.005 ± 0.001	0.284
	<i>Milk</i>	Leu	432 ± 184	569 ± 291
Ile		342 ± 148	441 ± 180	0.248
Tyr		41 ± 11	64 ± 31	0.071
Trp		192 ± 74	252 ± 90	0.170
KYN		2.4 ± 1.0	4.6 ± 1.8	0.012*
KYNA		7.9 ± 3.8	8.2 ± 2.6	0.840
XA		0.32 ± 0.12	0.31 ± 0.08	0.816
5HT		< LOD	<LOD	-
5HIAA		0.56 ± 0.27	0.81 ± 1.14	0.593
Melatonin		0.003 ± 0.002	0.003 ± 0.001	0.713
<i>Milk to plasma</i>	Leu	0.01 ± 0.00	0.01 ± 0.00	0.361
	Ile	0.03 ± 0.01	0.03 ± 0.01	0.174
	Tyr	0.009 ± 0.004	0.013 ± 0.006	0.152
	Trp	0.018 ± 0.008	0.020 ± 0.007	0.492
	KYN	0.002 ± 0.001	0.004 ± 0.002	0.012*
	KYNA	1.0 ± 0.4	1.2 ± 0.4	0.405
	XA	0.004 ± 0.001	0.003 ± 0.001	0.816
	5HT	< LOD	<LOD	-
	5HIAA	0.46 ± 0.17	0.67 ± 0.26	0.697
	Melatonin	0.46 ± 0.17	1.7 ± 0.8	0.157

617 Results are expressed as means of concentration (ng/mL) ± S.D. * p<0.05 vs wild-type

618









Fig. 1 Garcia-Lino et al.

A**B****C**

A) PARENTAL**B) Abcg2**






Fig. 4 Garcia-Lino et al.

Supplementary material

Table S1. Hydrogen bond acceptors (HBA) count and hydrogen bond donors (HBD) count for Trp metabolites detected in mouse samples. Data were obtained from U.S. National Library of Medicine (PubChem).


	Hydrogen bond acceptors (HBA) count	Hydrogen bond donors (HBD) count
KYNA	5	3
XA	5	3
KYN	4	2
AA	3	2
Trp	3	3
5HT	2	3
5HIAA	2	2






Wild-type and Abcg2^{-/-}



Y581Y and Y581S ABCG2



MDCKII transduced cells




Plasma and Milk Samples




Cell Culture Samples



LC-MS/MS



HPLC



HIGHLIGHTS

LC-MS/MS analysis of tryptophan metabolome in plasma and milk shows ABCG2 interaction

Abcg2 mediates milk secretion of metabolites of the kynurenine pathway in mice

Bovine ABCG2 Y581S polymorphism increases kynurenine concentration in milk

Kynurenine and kynurenic and anthranilic acid are *in vitro* substrates of murine Abcg2

The bovine ABCG2 Y581S polymorphism affects the *in vitro* transport of kynurenine

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: